N

Nippon Shinyaku Co Ltd
TSE:4516

Watchlist Manager
Nippon Shinyaku Co Ltd
TSE:4516
Watchlist
Price: 3 988 JPY 0.15% Market Closed
Market Cap: 268.7B JPY
Have any thoughts about
Nippon Shinyaku Co Ltd?
Write Note

Nippon Shinyaku Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nippon Shinyaku Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
N
Nippon Shinyaku Co Ltd
TSE:4516
Current Portion of Long-Term Debt
ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Current Portion of Long-Term Debt
ÂĄ624.1B
CAGR 3-Years
43%
CAGR 5-Years
29%
CAGR 10-Years
14%
Daiichi Sankyo Co Ltd
TSE:4568
Current Portion of Long-Term Debt
ÂĄ400m
CAGR 3-Years
-73%
CAGR 5-Years
-60%
CAGR 10-Years
-43%
Otsuka Holdings Co Ltd
TSE:4578
Current Portion of Long-Term Debt
ÂĄ191.2B
CAGR 3-Years
57%
CAGR 5-Years
20%
CAGR 10-Years
9%
Chugai Pharmaceutical Co Ltd
TSE:4519
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Current Portion of Long-Term Debt
ÂĄ307.3B
CAGR 3-Years
43%
CAGR 5-Years
47%
CAGR 10-Years
45%
No Stocks Found

Nippon Shinyaku Co Ltd
Glance View

Market Cap
268.7B JPY
Industry
Pharmaceuticals

Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.

Intrinsic Value
4 781.58 JPY
Undervaluation 17%
Intrinsic Value
Price
N

See Also

What is Nippon Shinyaku Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.3B JPY

Based on the financial report for Sep 30, 2024, Nippon Shinyaku Co Ltd's Current Portion of Long-Term Debt amounts to 1.3B JPY.

What is Nippon Shinyaku Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
-3%

Over the last year, the Current Portion of Long-Term Debt growth was -3%.

Back to Top